Live Breaking News & Updates on Lysine demethylase

Stay updated with breaking news from Lysine demethylase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Tachyon Presents Preclinical Data on the Company's Novel KDM4 inhibitor, TACH101, at the 2022 AACR Annual Meeting

HOUSTON--(BUSINESS WIRE)--Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private biotechnology company developing transformative cancer therapies against novel targets, today shared preclinical data for TACH101, the Company’s first-in-class KDM4 inhibitor, at the American Association for Cancer Research...

United-states , American , Frank-perabo , American-association-for-cancer-research , Ernestn-morial-convention-center , Tachyon-therapeutics-inc , Tachyon-therapeutics , American-association , Cancer-research , Annual-meeting , Convention-center , New-orleans

New epigenetic regulatory mechanisms involved in multiple myeloma growth

An international team of researchers has analyzed the function of the histone demethylase KDM5A in multiple myeloma, one of the three major hematological cancers, and clarified the mechanism by which it promotes myeloma cell proliferation. They also developed a novel KDM5 inhibitor and showed that it inhibits cancer cell growth in a myeloma mouse model. The researchers expect that new therapies targeting KDM5A will be developed in the future.

Japan , United-kingdom , Hiroto-ohguchi , Kumamoto-university , Dana-farber-cancer-institute , Associate-professor-hiroto-ohguchi , Blood-cancer-discovery , Lysine-demethylase , Biochemistry , Enetics , Hysiology , Iochemistry